RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of Cudetaxestat (BLD-0409) Assessed Across Three Dose Ranges With or Without Standard of Care (Nintedanib or Pirfenidone) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cudetaxestat (Primary) ; Nintedanib; Pirfenidone
Indications Idiopathic pulmonary fibrosis
Focus Proof of concept; Therapeutic Use
Acronyms RESPIRARE
Sponsors Blade Therapeutics

Most Recent Events

04 Sep 2022 According to a Blade Therapeutics media release, trial design presented at European Respiratory Society (ERS) International Congress 2022
10 May 2022 Status changed from planning to not yet recruiting.
11 Apr 2022 Planned number of patients changed to 200.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight